BioNTech SE Files Updated Articles of Association

TL;DR

BioNTech SE updated its German Articles of Association, filed with the SEC today.

AI Summary

BioNTech SE filed a Form 6-K on June 17, 2025, to report an English translation of its current Articles of Association. These updated articles were registered with the commercial register in Germany.

Why It Matters

Changes to a company's articles of association can impact its corporate governance and operational framework, potentially affecting shareholder rights and strategic decisions.

Risk Assessment

Risk Level: low — This filing is administrative, providing an updated version of the company's governing documents without disclosing new financial or operational information.

Key Players & Entities

• BioNTech SE (company) — Registrant
• 0001776985-25-000043 (filing_id) — Accession Number
• June 17, 2025 (date) — Filing Date

FAQ

From the Filing

0001776985-25-000043.txt : 20250617 0001776985-25-000043.hdr.sgml : 20250617 20250617164042 ACCESSION NUMBER: 0001776985-25-000043 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250617 DATE AS OF CHANGE: 20250617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251053885 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-karticlesofassociati.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K An English translation of BioNTech SE’s current Articles of Association, which were registered with the commercial register ( Handelsregister ) of the local court ( Amtsgericht ) of Mainz, Germany effective as of May 30, 2025, is attached hereto as Exhibit 99.1. Exhibit 99.1 shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and incorporated by reference herein. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: June 17, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Articles of Association of the Registrant EX-99.1 2 a991biontechsearticlesofas.htm EX-99.1 Document Convenience Translation. The German version is authoritative Exhibit 99.1 E ARTICLES OF ASSOCIATION OF BIONTECH SE I. General Provisions § 1 Company Name, Registered Office and Financial Year (1) The name of the Company is “BioNTech SE”. (2) The Company has its registered office in Mainz, Germany. (3) The financial year is the calendar year. § 2 Purpose of Enterprise (1) The purpose of the Company is the research and development, manufacture and marketing of immunological and RNA-based drugs and test methods for the diagnosis, prevention and treatment of cancer, infectious diseases and other serious diseases. (2) The Company may undertake all transactions and actions that are expedient for serving the Company’s purpose. It is also authorized to establish and acquire other companies and to invest in other companies, as well as to manage such companies or to limit itself to the administration of the investment. § 3 Announcements All of the Company’s announcements shall be made exclusively in the German Federal Gazette (Bundesanzeiger). II. Share Capital and Shares § 4    Amount and Divisio